Lecanemab gets positive CDA-AMC reimbursement nod in Canada
Eisai and Biogen have received a final positive recommendation from Canada's Drug Agency (CDA-AMC) supporting public reimbursement of lecanemab (LEQEMBI) for patients with mild cognitive impairment or mild dementia due to Alzheimer's disease. The decision follows a reconsideration process and represents a significant step toward funded access in Canada, where more than 770,000 people were estimated to be living with dementia in 2025.
The recommendation does not itself confer reimbursement. The next procedural stage is price negotiation through the pan-Canadian Pharmaceutical Alliance (pCPA), after which individual provincial and territorial public drug plans will each make their own coverage decisions. That pathway can extend over many months, meaning patients in Canada could still face a material wait before publicly funded access is available.
The drug and its regulatory standing
Lecanemab is a humanised IgG1 monoclonal antibody that targets aggregated soluble and insoluble forms of amyloid-beta, including protofibrils, which are thought to be among the more neurotoxic forms of the protein. The drug originated from a research alliance between Eisai and Swedish biotech BioArctic and has now been approved in 53 countries and regions, including the US, UK, Japan, China and across Europe.
The commercial offering has expanded since the initial intravenous fortnightly regimen. Eisai secured US FDA approval for a subcutaneous maintenance dose in August 2025 and for subcutaneous initiation treatment in July 2026. Applications for the subcutaneous formulations are under regulatory review in several additional markets, including Japan and China, where Priority Review designation has been granted. The availability of a self-administered subcutaneous option is commercially meaningful: it could ease the burden on infusion centres and broaden uptake in markets where the drug gains reimbursement.
Market context
The positive CDA-AMC recommendation lands at a moment when the anti-amyloid class is still working to establish itself commercially after years of clinical and regulatory turbulence. Lecanemab and donanemab, developed by Eli Lilly, are the two principal disease-modifying therapies now approved in the US, both targeting amyloid clearance in early-stage disease. Payer acceptance has been the critical bottleneck in most markets, with health technology assessment bodies scrutinising the modest but statistically significant cognitive benefit against the cost of the therapy and the infrastructure required for patient monitoring, including MRI screening for amyloid-related imaging abnormalities (ARIA).
Canada's HTA landscape is broadly comparable to European markets in its emphasis on clinical utility and cost-effectiveness, and a positive CDA-AMC recommendation, even after reconsideration, carries weight for the pCPA negotiating process. Eisai and Biogen will be aware that the reimbursement terms eventually agreed will set a reference point watched by other markets.
Looking further ahead, Eisai is conducting the AHEAD 3-45 Phase 3 study in preclinical Alzheimer's disease, where participants are cognitively normal but carry elevated amyloid burden. If that study reads out positively, it could substantially expand the eligible population and reopen the health-economic debate in markets that have already drawn coverage boundaries around symptomatic early disease only. Results from AHEAD 3-45 are not yet expected imminently, and the timeline has not been publicly confirmed.